Ensem Therapeutics puts pan-KRAS and WRN into focus as AACR 2026 sharpens its precision oncology pitch

Read how Ensem Therapeutics is positioning ETX-929 and ETX-880 in the KRAS and MSI-H oncology races at AACR 2026.

Read how Ensem Therapeutics is positioning ETX-929 and ETX-880 in the KRAS and MSI-H oncology races at AACR 2026.